Nanogen-Aventis R&T Joint Venture - 500 Beiträge pro Seite

[ramjam]

Na, also: ein Schritt in die richtige Richtung!

Nanogen and Aventis R&T Form Joint Venture to be Named Nanogen Recognomics GMBH



- New Company to Develop Novel Applications and Products For the NanoChip™ System -

SAN DIEGO, CA, July 17, 2001 – Nanogen, Inc. (Nasdaq: NGEN) and Aventis Research & Technologies GmbH & Co KG of Frankfurt, Germany (Aventis R&T) today announced the formation of a new company, Nanogen Recognomics GmbH. The joint venture will combine Nanogen’s NanoChip™ technology and Aventis R&T´s intellectual property and expertise in synthetic oligonucleotide chemistry and advanced molecular biology to develop new products and applications for the NanoChip™ System.


Nanogen Recognomics will be based in Frankfurt, Germany, and led by Managing Director, Dr. Norbert Windhab, formerly an Aventis R&T employee. The new company is sixty percent owned by Nanogen and forty percent owned by Aventis R&T. The joint venture currently has twelve employees, who joined Nanogen Recognomics from Aventis R&T.


"We are excited to enter into this joint venture with our long-term collaborator, Aventis R&T, and we welcome the talented scientists who have joined Nanogen Recognomics," said Dr. Randy White, Nanogen’s Chief Executive Officer. "Establishing the joint venture was an important goal this year for Nanogen because it will allow us to develop new technologies that can benefit from the integration of electronics and biology. Additionally, it will allow Nanogen to continue to invest in research and development of the NanoChip™ technology, while maintaining internal focus on the development and commercialization of the NanoChip™ System for its planned entry into the clinical diagnostics market."


Aventis R&T has contributed to the funding of the new company and has brought in eighteen patents to the joint venture. In addition, Nanogen Recognomics will own several patent applications filed jointly by Nanogen and Aventis R&T. Nanogen has licensed certain aspects of its NanoChip™ technology to the new company and will commercialize new products and applications developed by the joint venture. Aventis R&T retains the right to utilize the former Aventis R&T patent portfolio in fields outside of the joint venture.


The Aventis R&T-Nanogen collaboration began in 1998 and includes several programs, including methods for investigating gene expression and for drug discovery with the development of high throughput screening of kinase inhibitors. These programs continue to remain separate from the joint venture. Nanogen Recognomics’ research and development efforts will include genetic-based in vitro human detection, diagnostics, screening and monitoring applications, including research into novel oligonucleotide attachment chemistries.


"We are pleased to have combined our efforts with Nanogen to form this new company," said Dr. Wolfgang Schueller, President of Aventis R&T. "Aventis R&T has recognized the demonstrated power of Nanogen’s electronic technology for many years, and believes significant new applications and products can be developed by combining Aventis R&T’s and Nanogen’s unique strengths."


Nanogen markets its NanoChip™ Molecular Biology Workstation system to scientists, genomics laboratories and clinical research laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen’s web site at www.nanogen.com.


Aventis Research & Technologies GmbH & Co KG is a subsidiary of Aventis Group, Strasbourg, France. The Aventis Group was created in December 1999 through the merger of Hoechst AG of Germany and Rhône-Poulenc S.A. of France.


This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether Nanogen Recognomics’ products under development can be successfully developed and commercialized, whether Nanogen Recognomics’ patented and licensed inventions can be successfully incorporated into commercial products, whether Nanogen Recognomics will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen and Nanogen Recognomics disclaims any intent or obligation to update these forward-looking statements.

[tst89]

Na dass ist doch mal `ne bombige Nachricht!!!

Ich hab`s ja bereits gesagt dass es mit Nanogen bald
aufwärts gehen wird!!!

Warten wir mal die heutigen Zahlen an der Nasdaq ab!!

Gruß an alle
Nanogen-Investoren

tst

[ramjam]

Ziemlich schwache Vorstellung gestern an der Nasdaq. Ich denke aber, daß nach etwas Nachdenken eine deutlichere Reaktion erfolgen wird.
Man muß sich das auf der Zunge zergehen lassen: Das ist ein JV mit einem der erfahrensten Anwender der Nanogentechnologie. Marktreife Produkte sind sicherlich noch nicht da, aber:
Die Zusammenarbeit wird viel intensiver werden, da nun alles in der Familie ist. Davon partizipieren beide Partner!
Welche Ziele hat der Kooperationspartner bisher verfolgt: Anwendungen für den Pharmabereich (s. meine Anmerkungen im anderen Thread)!
Fazit: Da ist nun Musik drin. Muß nur noch wahrgenommen werden.

ramjam

[tst89]

@ramjam

das denke ich doch auch...

ich werde wohl noch heute nachkaufen um meine Gewinnschwelle weiter nach untern zu verlagern....

Wie erstellt man neue eigene Threads?????????????????

Gruß
tst

[tst89]

@ramjam

Jetzt haben es anscheinend die Amis auch begriffen.

Wir sind schon bei 7,14 US $
Das ist ein Plus von über 10%.......

Ich denke jetzt sind einige endgültig aufgewacht.
In Deutschland werden wir also in Kürze wieder über
8 Euro sein!!

Auf zur 10!!!

Gruß
tst

[ambobobo]

@ All

Melde mich an Board.Auf noch viele gute News.

ambobobo

[tst89]

Tja jetzt ist ein bisserl die Luft raus in den USA.

Allerdings halten sich NGEN immer noch im Plus,
was man ja von der Nasdaq nicht behaupten kann.

[ambobobo]

@ tst89

Wird schon immer mit der Zeit solche
Meldungen gehen in USA nicht vergessen.

Ambobobo

[tst89]

Na guten Morgen!

Hab grad den Schlußkurs von Nanogen in den USA gesehen?!

Hat jemand `ne Ahnung warum Nanogen um 12% gesunken sind???

Auf bessere Kurse heute!!!

Gruß
tst

[ramjam]

Tja, das muß man wohl unter der Rubrik "sell on good news" ablegen. Wahrscheinlich haben einige institutionelle Anleger die Gelegenheit genutzt, um ihre Bestände an Biotechs abzubauen. Einige der Großen (Biogen) stehen mit etwas eingetrübten Aussichten da. Während man bei denen aufgrund hoher Umsätze leicht umschichten kann, gelingt dies bei small caps wie Nanogen nur bei guten Nachrichten, wenn auf der Käuferseite ein Gegengewicht da ist. Aber das sehen wir ja seit geraumer Zeit, daß die ganze Branche verhauen wird, wenn einer ausrutscht.
Bin mal gespannt wie es heute in USA läuft. Könnte mir vorstellen, daß nach dem sell out gestern heute ein schöner rebound kommt.

Gruß ramjam

[Koy.aan.is.qatsi]

Hmm weiss auch nicht gab eigentlich keine Meldungen.
Aber -12.8 Prozent bei ziemlich hohen Umsätzen (128000;
Vortag nur ca. die Hälfte). ist das nur auf die schlechte
Marktlage zurückzuführen oder weis da einer mehr. Die
nächsten Zahlen kommen am 31.07. Die letzten 2-3 Stunden
wurden gestern mehrere große Pakete (5000-10000 Stück)
"verkloppt". Da hat sich bestimmt ein Insti verabschiedet
der Geld brauchte oder mehr weis. Bloß gut das ich mir noch
keine reingelegt habe. Und ich dachte 6 Dollar wäre ein guter
Boden. Aber eh ich mir Ami-Biotech wieder reinlege, müssen
sich erst mal meine NM-Papiere sich wieder "finden". Und die
machen Gewinn. Aber wen interessiert das zur Zeit schon.
NM kannste jetzt und vermutlich die nächsten 6-12 links
liegen lassen. Also was bleibt ist AMI-Biotech, obwohl die
meisten eine horrormäßige hohe Bewertung haben. NAJA SCHAUN MER MAL.....

[tst89]

@ Koy.aan.is.qatsi

kommen neue quartalszahlen von nanogen am 31.7.????
wie sind die prognosen???

gruß
tst

[ambobobo]

Habe heute noch mal nachgekauft zu 7 Euro
denke mal die Ammis werden heute die Zins-
fantasie ausleben.

ambobobo

Ps: Habe da noch was tolles entdeckt
ungebrochener Aufwertstrend schreibe
einfach mal die WKN hier rein
939210
BITTE NICHT ALS PUSCHVERSUCH ANSEHEN.
DAS WÜRDE ICH NICHT HIER MACHEN.DAZU
WERDEN WIR ZU WENIG GELESEN.

Leider

[DagobertDag]

Tja Leute : verstehen tue ich das auch nicht. Immerhin hat die Aktie nach dem Höchstkurs 21% verloren.
Ich habe aber auch keine anderen News gefunden. handelt es sich wirklich nur "sell on good News" ?
Vorbörslich scheint es so ob es eine kleine Kurserhohlung gibt.



Hier noch mal in deutsch

Dienstag Juli 17, 8:03 morgens östliche Zeit
Pressekommuniqué
QUELLE: Nanogen, Inc..
Zu benennende Joint Venture des Formulars & Nanogen und Aventis R T Nanogen Recognomics GmbH
- New Company zum Entwickeln von von Romananwendungen und -produkten für das NanoChip(TM) System -
San Diego, Juli 17 / PRNewswire / -- Nanogen, Inc. (Nasdaq: NGEN - Nachrichten ) und Technologien GmbH & Co Kilogramm & Forschung Aventis von Frankfurt, Deutschland (Aventis R & T) verkündete heute die Anordnung einer neuen Firma, Nanogen Recognomics GmbH. Die Joint Venture kombiniert Technologie Nanogen NanoChip(TM) und geistiges Eigentum & und Sachkenntnis t Aventis R in der synthetischen Oligonucleotidechemie und in vorgerückter molekularer Biologie, um neue Produkte und Anwendungen für das NanoChip(TM) System zu entwickeln.

Nanogen Recognomics wird basiert in Frankfurt, Deutschland und von geschäftsführendem Geschäftsführer, Dr. Norbert Windhab, früher ein Angestellter Aventis R & T geführt. Die neue Firma beträgt sechzig Prozent, das von Nanogen besessen wird und vierzig Prozent, das durch Joint Venture Aventis & R T. The hat besessen wird aktuell, zwölf Angestellte, die Nanogen Recognomics von Aventis R T & verbanden.

``We werden aufgeregt, um an dieser Joint Venture mit unserem langfristigen Mitarbeiter, Aventis R T & teilzunehmen, und wir begrüßen die begabten Wissenschaftler, die Nanogen Recognomics verbunden haben, ` ` sagten Dr. Randy White, Generaldirektor Nanogen. ``Establishing die Joint Venture war ein wichtiges Ziel dieses Jahr für Nanogen, weil es uns erlaubt, neue Technologien zu entwickeln, die von der Integration von Elektronik und von Biologie profitieren können. Zusätzlich läßt es Nanogen fortfahren, in der Forschung und in der Entwicklung der NanoChip(TM) Technologie zu investieren, während interner Fokus Beibehaltens auf der Entwicklung und der Kommerzialisierung des NanoChip(TM) Systems für seinen geplanten Eintrag in den klinischen Diagnose Markt. ` `,

Aventis R & T hat zur Finanzierung der neuen Firma beigetragen und hat achtzehn Patente zur Joint Venture geholt. Zusätzlich besitzt Nanogen Recognomics einige Patentanfragen, die gemeinsam von Nanogen archiviert werden und Aventis R & T. Nanogen hat bestimmte Aspekte seiner NanoChip(TM) Technologie zur neuen Firma genehmigt und wird neue Produkte und die Anwendungen in den Handel bringen, die durch die Joint Venture entwickelt werden. Aventis R & T behält das Recht bei, die ehemalige Patentmappe Aventis & R T auf Gebieten außerhalb der Joint Ventures zu verwenden.

Die Zusammenarbeit Aventis & R T-Nanogen fing 1998 an und umfaßt einige Programme, einschließlich der Methoden für das Nachforschen des Genausdruckes und für Drogeentdeckung mit der Entwicklung der hohen Durchsatzsiebung der Kinasehemmnisse. Diese Programme fahren fort, getrennt von der Joint Venture zu bleiben. Forschung und Entwicklung Nanogen Recognomics Bemühungen schließen genetisch-genetic-based menschliche in-vitroabfragung, Diagnose und Siebung und die Überwachung Anwendungen, einschließlich der Forschung in Romanoligonucleotide-Zubehörchemie mit ein.

``We freuen sich, unsere Bemühungen mit Nanogen kombiniert zu haben, diese neue Firma zu bilden, ` ` sagte Dr. Wolfgang Schueller, Präsident von Aventis R & T. ``Aventis R & T hat erkannt die demonstrierte Energie der elektronischen Technologie Nanogen für viele Jahre und glaubt, daß bedeutende Neuanmeldungen und Produkte entwickelt werden können, indem man kombiniert eindeutige Stärken & t und Nanogen Aventis R. ` `,

Nanogen vermarktet sein NanoChip(TM) molekulares Biologiearbeitsplatzsystem zu den Wissenschaftlern, zu den genomicslabors und zu den klinischen Forschung Labors und stellt neue Standards für das SNP-Zählen ein. Zusätzlich entwickelt Nanogen eine Reihe Elektronik-electronics-based Produkte, um Forschern zu helfen und klinische healthcareversorger beschleunigen ihr praktisches Verständnis und Gebrauch von genomic Informationen. Die eingeführten und unter Produkte Entwicklung sollen schnelle und genaue Analyse von DNA, von RNS und von Proteinen zur Verfügung stellen und können schließlich ``bridge ` ` der Abstand zwischen der Forschung und den klinischen Einstellungen. Das System Nanogen ist für nur Forschung Gebrauch und nicht für Gebrauch in den Diagnoseverfahren bestimmt. Zu zusätzlicher Information besuchen Sie bitte Web site Nanogen an www.nanogen.com .

Technologien GmbH & Co Kilogramm & Forschung Aventis ist eine Tochtergesellschaft der Gruppe Aventis, Straßburg, Frankreich. Die Gruppe Aventis wurde im Dezember 1999 durch die Fusion von Hoechst AG von Deutschland und von Rhone-Poulenc S.A. von Frankreich erstellt.

**time-out** dies press Pressekommuniqué enthalten Vorwärts--forward-looking Anweisung das sein abhängig von Gefahr und Ungewißheit das können verursachen tatsächlich Resultat zu unterscheiden materiell von festlegen in d Vorwärts--forward-looking Anweisung, mit.einschließen ob Nanogen Recognomics Produkt unter Entwicklung können sein erfolgreich entwickeln und in den Handel bringen, ob Nanogen Recognomics patentieren und genehmigen Erfindung können sein erfolgreich verbinden in commercial Handelsprodukt, ob Nanogen Recognomics werden fortsetzen zu sein finanzieren, und ander Gefahr und Ungewißheit behandeln unter d Untertitel ``Factors das mögen beeinflussen Resultat ` und anderwohin in Nanogen Formular 10-K für d Jahr beenden Dezember 31, 2000 archivieren mit d Sicherheit und Austausch Kommission. Diese Vorwärts-forward-looking Anweisungen sprechen nur ab dem Datum hiervon. Nanogen und Nanogen Recognomics dementiert jede mögliche Absicht oder Verpflichtung, diese Vorwärts-forward-looking Anweisungen zu aktualisieren.

QUELLE: Nanogen, Inc

[tst89]

Ich hoffe doch dass es einen guten Rebound gibt.

Ich habe gestern (leider vor dem Kursrutsch) zu
7,40 EUR nochmal nachgekauft, da ich trotz diesem kleinen
Minus gestern sehr an Nanogen glaube.

[ambobobo]

@ tst89

Ich bin auch von Nanogen überzeugt.Das waren ja auch
super News also bleiben wir mal locker und warten ab.
Ich bin sicher wir werden bald wieder Kurse um 8 Euro
und höher sehen.
Allein die letzte News zeigt doch das Nanogen auf
den besten Weg ist.

ambobobo

[tst89]

Na also, es geht doch!

Wenigstens sind wir wieder über der 6$-Marke!!!!

Gruß
an
alle
Nanogen-Investoren

P.S. Wisst Ihr wann Nanogen Zahlen veröffentlicht?

[DagobertDag]

10.39 Uhr 4900
11.06 Uhr 2400
11.07 Uhr 2200

das sind ganz schöne verkauforders. Möchte wissen wer da so viele Stücke anbietet.
Ich vermute mal das wir heute wieder unter die 6$ Marke fallen.

[DagobertDag]

11.15.18 Uhr 1000 Stück
11.15.26 Uhr 1000 Stück
Das gefällt mir gar nicht.!

[tst89]

@dagobert dag

immer mit der ruhe!!!

ich denke schon dass wir über der 6$ Grenze schließen.

Momentan schauts ja ganz gut aus!

Gruß
tst

[ambobobo]

Jo, die 6$ hat gehalten aber morgen werden
wir wohl Kaufkurse bekommen
Naja,wir haben ja Zeit.

ambobobo

[tst89]

@ ambobobo

denkst Du wir bekommen neue Kaufkurse aufgrund
von dem schlechten Nasdaq-Finish gestern??

Keine neue Meldung von Nanogen, oder???

Gruß
tst

[ambobobo]

@ tst89

Nein, nein ich meinte aufgrund
der Nasdaq Vorgaben.

ambobobo

[tst89]

@ ambobobo

da bin ich ja beruhigt, dachte ich hätte eine schlechte
nachricht nicht mitbekommen.

Also hoffen wir dass die 6$-Grenze heute auch hält, damit
wir nächste Woche dafür voll durchstarten können.

In diesem Sinne
erholsames Wochenende

Gruß
tst

[ambobobo]

@ tst89

Jo, danke dir auch Erholung
tut uns wohl allen gut

Ob die 6$ heute hält? Ich
glaube es fast nicht.Aber
wir werden sie,wenn sie heute
fällt,ganz schnell wieder haben.

An alle schönes Wochenende.

ambobobo

[ambobobo]

@ tst89

Hier kannst du alle News sehen.Dann bist
du immer voll informiert.


http://www.earnings.com/fin/newsDetail.jsp?tckr=NUFO&eff=200…

[ambobobo]

@ all

Ich habe mal nachgeschaut wieviele Shortys
in Nanogen sind und kann mit Freude feststellen
das es nur sehr wenige sind.Im Vergleich zu
anderen Aktien oder auch Bio`s die kleinste
Position.Das sollte uns doch auftrieb geben.
Hat natürlich auch sein negative Seite,bei
einer Shortsequens wird sich bei uns nicht
soviel tun
Aber dafür halten die Shorty`s wohl unsere
Aktie nicht für überbewertet was ich auch
so sehe

ambobobo

[ambobobo]

Jungens ich habe einen tollen Film
entdeckt

http://www.tnt.uni-hannover.de/org/whois/wissmit/weis/tmp/fu…

Ist der nicht toll?

[fishey]

Werden heute die Tiefs von Anfang Mai getestet oder gibt`s da fundamentales?

FISHEY

[saali]

Hallo !

Rechtstreitigkeit mit Motorola beigelegt.

Erst mal keine Reaktion in USA.

Abwarten auf Quartalsergebnisse am 31 juli.

Mal sehen was es gibt.

Nanogen Reaches Settlement With Motorola, Genometrix and MIT
SAN DIEGO, July 24 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) and Motorola,
Inc. (NYSE: MOT - news) today announced a settlement agreement concluding the declaratory
judgment action by Nanogen against Motorola, Genometrix, Inc. and Massachusetts Institute of
Technology (``MIT``) and Motorola`s counterclaim against Nanogen. Nanogen had filed its
complaint in April 2000, alleging non-infringement and invalidity of U.S. Patent No. 5,653,939,
entitled ``Optical and Electrical Methods and Apparatus for Molecular Detection`` (the ```939
Patent``), and Motorola filed a counterclaim in May 2000, alleging infringement of the `939
Patent. In connection with the settlement, Nanogen has secured a license from Motorola to
Claims 16 and 39 of the `939 Patent. In exchange, Nanogen will make a one-time aggregate
payment of $5 million in cash and stock to the parties involved. The settlement does not
include any cross-licensing provisions of Nanogen`s technology to Motorola, Genometrix or
MIT. The lawsuit has now been dismissed.

``Nanogen is pleased with the settlement, which disposes of claims of infringement arising
from the `939 Patent. Nanogen has now obtained freedom to operate under this patent. By
coming to a settlement, both companies also avoid further legal costs,`` said Randy White,
Ph.D., Chief Executive Officer of Nanogen. ``We are pleased to put the action behind us and
we will continue to commercialize the NanoChip(TM) Molecular Biology Workstation in the
clinical research market and to develop it for potential use in the clinical diagnostics market.``

The license grant from Motorola follows the grant of a license to Nanogen to the `939 Patent
from Beckman Coulter, Inc. in May 2000. The `939 Patent was originally assigned to MIT, which
licensed the `939 Patent to Beckman Coulter, Inc. in 1993. In 1994, MIT licensed the `939
Patent to Genometrix, Inc., which subsequently granted sublicensing rights to Motorola in 1999.


``Motorola is satisfied with this settlement and sees that this is a positive event for the overall
life sciences industry,`` said George Turner, Corporate Vice President and General Manager,
Motorola Life Sciences. ``It underscores the value of our intellectual property while clearly
promoting and contributing to advances in drug discovery and development.``

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists,
genomics laboratories and clinical research laboratories, setting new standards for SNP
scoring. In addition, Nanogen is developing a series of electronics-based products to help
researchers and clinical healthcare providers accelerate their practical understanding and use
of genomic information. The products introduced and under development are intended to
provide quick and accurate analysis of DNA, RNA and proteins, and may eventually ``bridge``
the gap between the research and clinical settings. The Nanogen system is intended for
research use only and not for use in diagnostic procedures. For additional information please
visit Nanogen`s web site at www.nanogen.com.

Motorola, Inc., is a global leader in providing integrated communications and embedded
electronic solutions. Sales in 2000 were $37.6 billion. Motorola Life Sciences is developing
products which enable the delivery of better healthcare through the understanding and practical
application of genomics. The organization is developing products that will enable scientists and
healthcare professionals to quickly and accurately analyze DNA and RNA. The CodeLink(TM)
biochip system is used for research applications, while the eSensor(TM) DNA detection
system is used for clinical and industrial diagnostic applications. For more information about
the CodeLink or eSensor detection family of products, visit Motorola at
www.motorola.com/lifesciences.

This press release contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those set forth in the
forward-looking statements, including whether Nanogen`s products under development can be
successfully developed and commercialized, whether Nanogen`s patented and licensed
inventions can be successfully incorporated into commercial products, and other risks and
uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in
Nanogen`s Form 10-K for the year ended December 31, 2000 filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof.
Nanogen disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Nanogen, Inc.

[Maxxtro]

Hallo all..

Wurd ja auch langsam Zeit das dieser Klotz mit Motorola beigelegt wurde.Jetzt kanns eigentlich nur nach oben gehen....wenn die Quartalszahlen mitspielen.

MfG..

[tst89]

@saali

Wann ist denn die Nachricht mit Motorola rausgekommen (Uhrzeit?)

@all

Hallo allerseits!!

Super! Nachdem dieses Problem mit Motorola beseitigt ist wird es zwangsläufig aufwärts gehen.

Hat jemand schon eine Ahnung (Gerüchte gehört) wie denn die Quartalszahlen aussehen werden?

Viele Grüße
tst

P.S. Aber immerhin haben diese Kurse was positives! Nachkaufen ohne Reue! *g*

[ambobobo]

@ tst89


Nanogen to Hold Conference Call on 2001 Second Quarter Financial Results
SAN DIEGO, Jul 24, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) will hold a conference call on Tuesday, July 31, 2001 at 4:30 p.m. Eastern Time to discuss 2001 second quarter financial results.

Nanogen management will host the conference call. Audio of the call will be available by live webcast and archived until August 7, 2001, through PR Newswire at http://www.videonewswire.com/event.asp?id=316. Information about the conference call and webcast is also available at the Company`s website www.nanogen.com.

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists, genomics laboratories and clinical research laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

ambobobo

[tst89]

@ ambobobo

Tja, da können wir nur hoffen oder???

Sprich am 31.07. um 22.30h MEZ werden wir schlauer sein....

Viele Grüße
tst

[ambobobo]

@tst89

Na,ich denke wir werden positiv
überrascht.Die 6$ haben wir uns
wiedergeholt.

ambobobo

[tst89]

@ ambobobo

Stimmt!

Die 6$ haben tatsächlich gehalten *g*
Na dann auf zur 7$-Marke....

Wird langsam Zeit dass die Amis aufwachen.

Gruß
tst

[tst89]

@ ambobobo

Stimmt!

Die 6$ haben tatsächlich gehalten *g*
Na dann auf zur 7$-Marke....

Wird langsam Zeit dass die Amis aufwachen.

Gruß
tst

[ambobobo]

Na bitte wir sind auf dem besten Weg
wieder nach Norden zu ziehen.Sehr stark
wie die ganze Zeit die 6$ gahalten hat
wo andere Werte mal schnell 12% verlohren
haben ich sehe das sehr positiv.
Auch schaue ich immer nach Shortpositionen
und kann froh verkünden das auch weiterhin
kaum Shortys drinnen sind,und nicht mehr
geworden sind.
Also auf die 8$ da werden wir schnell sein denke
ich und Zahlen kommen ja auch bald

ambobobo

[tst89]

@ambobobo

Na dann auf zur nächsten Marke!!! *g*

Aber Du klingst ziemlich sicher dass die Quartalszahlen nächste Woche ganz gut ausfallen werden. Hast Du schon irgendwelche Prognosen gehört?

Gruß
tst

[ambobobo]

@ Tst89

Wenn du dir einfach mal die letzten Meldungen
durchliest erkennt man den Weg.Da steckt was
dahinter,eine Aventis würde sonnst kaum mit
Nanogen zusammenarbeiten.

ambobobo

[ramjam]

Genau! Ein JV ist die ideale Lösung. Beide Partner profitieren am besten von dem Gemeinschaftsunternehmen Nanogen Recognomics, wenn Informationen frei fließen und Entwicklungen so in der kürzesten Zeit umgesetzt werden können.

Gruß, ramjam

[saali]

@ ambobobo

Woher hast du die Infos das kaum Shortpositionen offen sind ?

Soweit ich mitbekommen habe Stand letzte Woche ca. 500.000 St.

Nebenbei - ich würde es toll finden wenn 10.000.000 short währen. Die müßten nämlich alle noch eindecken.

[ambobobo]

@ Saali

Erst mal die Shortpositionen leider gehen die
aus Nanogen raus schnüff.

Short Interest Search



SHORT Interest Tables | By Company

Ticker Company Name Previous Month Current Month Shares Decreased

NGEN Nanogen, Inc. 477,571 440,161 -37,410

Days - to - Cover Ratio % Shares Decreased

5.3 -7.8



Ja die lümmeln sich raus heisst auch BODEN bie 6$
naja ich geb dir mal zwei URL`S

http://www.shortinterest.com/tools/toolbox/largestshortposit…

und

[urlhttp://www.viwes.com/invest/shorts/query.cgiurl[/url]


Willst du auch die Flüstererwartungen und weitere URL`s??


ambobobo

[ambobobo]

Ups Klammer vergessen.

http://www.viwes.com/invest/shorts/query.cgiurl

ambobobo

[humm]

http://www.viwes.com/invest/shorts
http://www.shortinterest.com/tools/toolbox/

[tst89]

Heute werden die Quartalszahlen bekannt gegeben!!!

Wir können gespannt sein um 22.30h MEZ die Ergebnisse präsentiert!

also

WATCH OUT!!!

Gruß
tst

[ambobobo]

@ all

Wer sie zuerst hat bitte hier
reinstellen,ich kann es kaum
erwarten grins.

[tst89]

@all

es schaut momentan eigentlich sehr positiv für heute abend
aus, da an der Nasdaq sehr viel Nanogen gekauft und dafür bisher kaum welches verkauft wurde!!!!

Bisheriges Plus fast +5%

Und dass wenige Stunden vor den Quartalszahlen!!
Wissen da einige etwa schon mehr als wir???

Ich bin gespannt!

Viele Grüße
tst

[ambobobo]

@ tst89

Stimmt wenn ihr euch mal in letzter
Zeit angeschaut habt wer Zahlen brachte
die OK waren war meistens schon am
Handelstag im Plus.
Bei Nanogen liegen jetzt grosse Orders
in Kauf denke mal die letzten Shorty`s
bekommen kalte Füsse.


ambobobo

[ambobobo]

Nanogen Reports 2001 Second Quarter Results
SAN DIEGO, Jul 31, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2001.

Total revenues for the quarter ended 2001 were $2.7 million compared to $2.4 million for the same period in 2000. Revenue recognized during the quarter was primarily earned in connection with sponsored research programs from the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $302,000 in revenue recognized during the quarter resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.

Nanogen sold three NanoChip(TM) Molecular Biology Workstations during the quarter ended June 30, 2001. The three sales included two sales recorded as product revenue and one sale recorded as sponsored research revenue and funded via a corporate alliance.

For the first six months of 2001, total revenues were $5.7 million as compared to $4.7 million for the same period in 2000. Revenue recognized during the six months ended June 30, 2001 was primarily earned in connection with sponsored research programs with the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $531,000 in revenue recognized in the six months ended June 30, 2001 resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.

The Company`s cash, cash equivalents and short-term investment balance at June 30, 2001 was $78.4 million. During the quarter ended June 30, 2001, the Company incurred a one-time charge of $5 million related to a settlement of a patent litigation matter involving Motorola, Inc., Genometrix, Inc. and the Massachusetts Institute of Technology. Absent the impact of charges related to the litigation and settlement of this matter, total operating expenses for the second quarter of 2001 were $10.1 million, as compared to $7.9 million for the same period in 2000. For the first six months of 2001, absent these charges, total operating expenses were $19.8 million compared to $14.4 million for the same period in 2000. The increase in operating expenses for the second quarter of 2001 and for the first six months of 2001, as compared to the same periods in 2000, are primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization.

The reported net loss for the quarter and six-month period ended June 30, 2001, inclusive of the litigation and settlement charges noted above, was $11.8 million, or $0.56 per share and $18.0 million, or $0.87 per share, respectively. For the quarter ended June 30, 2001, excluding the litigation and settlement charges noted above of $5.5 million, the Company reported a net loss of $6.2 million or $0.30 per share, compared to a net loss of $4.1 million or $0.20 per share for the same period in 2000. For the first six months of 2001, excluding the litigation and settlement charges noted above of $6.3 million, the Company reported a net loss of $11.7 million or $0.56 per share, compared to a net loss of $7.8 million or $0.40 per share for the same period in 2000.





Highlights for the second quarter, ended June 30, 2001 include:

-- The formation of a joint venture with Aventis R&T named Nanogen
Recognomics GmbH, including the assignment by Aventis R&T of 18 patents
to this new joint venture. Funding for the joint venture is initially
provided by Aventis R&T.
-- Appointment of two executives: V. Randy White as Chief Executive
Officer and Gerard A. Wills as Chief Financial Officer.
-- Award of an additional six United States and three foreign patents to
Nanogen bringing the total number of U.S. patents to 27. In addition,
the joint venture between Nanogen and Becton Dickinson was issued its
first patent.
-- Initiation of external testing for High Throughput Screening of Protein
Kinases as an alternative application around Nanogen`s core electronics
technology.


Additionally, Nanogen resolved its litigation with Motorola, Genometrix and MIT by securing a license from Motorola to Claims 16 and 39 of U.S. Patent No. 5,653,939 entitled "Optical and Electrical Methods and Apparatus for Molecular Detection." This provides Nanogen the freedom to operate under patent claims relating to electronic hybridization. Nanogen resolved the litigation without having to provide Motorola access to Nanogen`s own technology. Nanogen remains the only current provider of commercially available electronic hybridization products.

"We are pleased with the progress we made during the second quarter, including progress toward our planned entry into the clinical diagnostics market," said Randy White, Ph.D., Nanogen`s Chief Executive Officer. "This included internal development of genetic content to be used with the NanoChip(TM) cartridges to support the clinical research market and eventually the clinical diagnostics market, where there is high demand for pre-made arrays. Additionally, we continued to build and train our sales and marketing team and applications specialists to support our customer base and commercialization efforts of the NanoChip(TM) Molecular Biology Workstation."

Webcast of Conference Call

Nanogen management will hold a conference call to discuss second quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available at http://www.videonewswire.com/event.asp?id=316 and through a link that is posted on Nanogen`s website at http://www.nanogen.com. A telephone replay of the conference call also will be available for 48 hours at 800-633-8284 (domestic) or 858-812-6440 (international), reservation #19399095. The webcast will be available on Nanogen`s website through August 7, 2001.

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists, genomics laboratories and clinical research laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be successfully commercialized, whether the patented inventions can be successfully incorporated into commercial products, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding sales or placements of its NanoChip(TM) Molecular Biology Workstation as it deems appropriate and as required by law.






NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

June 30, December 31,
2001 2000
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $20,419 $55,330
Short-term investments 57,938 39,759
Accounts receivable 1,413 1,322
Inventory 4,234 2,289
Other current assets 3,332 1,689
Total current assets 87,336 100,389

Property and equipment, net 5,444 5,373
Acquired technology rights, net 4,579 5,179
Restricted cash 164 164
Other assets 203 63
Total assets $97,726 $111,168


LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $622 $1,223
Accrued liabilities 5,419 4,095
Deferred revenue 151 360
Current portion of capital lease obligations 1,514 2,011
Total current liabilities 7,706 7,689

Capital lease obligations, less current portion 2,186 1,565
Other long-term liabilities 3,000 500
Total long-term liabilities 5,186 2,065

Stockholders` equity:
Convertible preferred stock, $.001 par
value, 5,000,000 shares authorized; no
shares issued and outstanding at June 30,
2001 and December 31, 2000 -- --

Common stock, $.001 par value, 50,000,000
shares authorized; 21,057,583 and
20,913,151 shares issued and outstanding
at June 30, 2001 and December 31, 2000,
respectively 21 21
Additional paid-in capital 194,198 193,459
Accumulated other comprehensive income 862 270
Deferred compensation (175) (325)
Notes receivable from officers (1,131) (1,099)
Accumulated deficit (108,941) (90,912)
Total stockholders` equity 84,834 101,414
Total liabilities and stockholders` equity $97,726 $111,168


NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)

Three months ended Six months ended
June 30, June 30,
2001 2000 2001 2000
Revenues:
Sales $302 $164 $531 $164
Sponsored research 2,055 1,704 4,401 3,566
Contract and grant revenue 358 484 723 934
Total revenues 2,715 2,352 5,655 4,664

Operating expenses:
Cost of sales 230 12 400 12
Research and development 4,414 4,515 9,199 8,758
Selling, general and
administrative 5,406 3,344 10,192 5,625
Litigation and settlement
of patent matter 5,511 -- 6,309 --
Total operating expenses 15,561 7,871 26,100 14,395
Loss from operations (12,846) (5,519) (20,445) (9,731)

Interest income, net 1,092 1,406 2,418 1,940
Gain (loss) on foreign
currency transactions 4 -- (2) --
Net loss $ (11,750) $ (4,113) $ (18,029) $ (7,791)

Net loss per share -
basic and diluted $(0.56) $(0.20) $(0.87) $(0.40)

Number of shares used in
computing net loss per
share - basic and diluted 20,847 20,208 20,802 19,513

[ambobobo]

Nanogen Reports 2001 Second Quarter Results
SAN DIEGO, Jul 31, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2001.

Total revenues for the quarter ended 2001 were $2.7 million compared to $2.4 million for the same period in 2000. Revenue recognized during the quarter was primarily earned in connection with sponsored research programs from the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $302,000 in revenue recognized during the quarter resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.

Nanogen sold three NanoChip(TM) Molecular Biology Workstations during the quarter ended June 30, 2001. The three sales included two sales recorded as product revenue and one sale recorded as sponsored research revenue and funded via a corporate alliance.

For the first six months of 2001, total revenues were $5.7 million as compared to $4.7 million for the same period in 2000. Revenue recognized during the six months ended June 30, 2001 was primarily earned in connection with sponsored research programs with the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $531,000 in revenue recognized in the six months ended June 30, 2001 resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.

The Company`s cash, cash equivalents and short-term investment balance at June 30, 2001 was $78.4 million. During the quarter ended June 30, 2001, the Company incurred a one-time charge of $5 million related to a settlement of a patent litigation matter involving Motorola, Inc., Genometrix, Inc. and the Massachusetts Institute of Technology. Absent the impact of charges related to the litigation and settlement of this matter, total operating expenses for the second quarter of 2001 were $10.1 million, as compared to $7.9 million for the same period in 2000. For the first six months of 2001, absent these charges, total operating expenses were $19.8 million compared to $14.4 million for the same period in 2000. The increase in operating expenses for the second quarter of 2001 and for the first six months of 2001, as compared to the same periods in 2000, are primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization.

The reported net loss for the quarter and six-month period ended June 30, 2001, inclusive of the litigation and settlement charges noted above, was $11.8 million, or $0.56 per share and $18.0 million, or $0.87 per share, respectively. For the quarter ended June 30, 2001, excluding the litigation and settlement charges noted above of $5.5 million, the Company reported a net loss of $6.2 million or $0.30 per share, compared to a net loss of $4.1 million or $0.20 per share for the same period in 2000. For the first six months of 2001, excluding the litigation and settlement charges noted above of $6.3 million, the Company reported a net loss of $11.7 million or $0.56 per share, compared to a net loss of $7.8 million or $0.40 per share for the same period in 2000.





Highlights for the second quarter, ended June 30, 2001 include:

-- The formation of a joint venture with Aventis R&T named Nanogen
Recognomics GmbH, including the assignment by Aventis R&T of 18 patents
to this new joint venture. Funding for the joint venture is initially
provided by Aventis R&T.
-- Appointment of two executives: V. Randy White as Chief Executive
Officer and Gerard A. Wills as Chief Financial Officer.
-- Award of an additional six United States and three foreign patents to
Nanogen bringing the total number of U.S. patents to 27. In addition,
the joint venture between Nanogen and Becton Dickinson was issued its
first patent.
-- Initiation of external testing for High Throughput Screening of Protein
Kinases as an alternative application around Nanogen`s core electronics
technology.


Additionally, Nanogen resolved its litigation with Motorola, Genometrix and MIT by securing a license from Motorola to Claims 16 and 39 of U.S. Patent No. 5,653,939 entitled "Optical and Electrical Methods and Apparatus for Molecular Detection." This provides Nanogen the freedom to operate under patent claims relating to electronic hybridization. Nanogen resolved the litigation without having to provide Motorola access to Nanogen`s own technology. Nanogen remains the only current provider of commercially available electronic hybridization products.

"We are pleased with the progress we made during the second quarter, including progress toward our planned entry into the clinical diagnostics market," said Randy White, Ph.D., Nanogen`s Chief Executive Officer. "This included internal development of genetic content to be used with the NanoChip(TM) cartridges to support the clinical research market and eventually the clinical diagnostics market, where there is high demand for pre-made arrays. Additionally, we continued to build and train our sales and marketing team and applications specialists to support our customer base and commercialization efforts of the NanoChip(TM) Molecular Biology Workstation."

Webcast of Conference Call

Nanogen management will hold a conference call to discuss second quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available at http://www.videonewswire.com/event.asp?id=316 and through a link that is posted on Nanogen`s website at http://www.nanogen.com. A telephone replay of the conference call also will be available for 48 hours at 800-633-8284 (domestic) or 858-812-6440 (international), reservation #19399095. The webcast will be available on Nanogen`s website through August 7, 2001.

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists, genomics laboratories and clinical research laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be successfully commercialized, whether the patented inventions can be successfully incorporated into commercial products, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding sales or placements of its NanoChip(TM) Molecular Biology Workstation as it deems appropriate and as required by law.






NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

June 30, December 31,
2001 2000
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $20,419 $55,330
Short-term investments 57,938 39,759
Accounts receivable 1,413 1,322
Inventory 4,234 2,289
Other current assets 3,332 1,689
Total current assets 87,336 100,389

Property and equipment, net 5,444 5,373
Acquired technology rights, net 4,579 5,179
Restricted cash 164 164
Other assets 203 63
Total assets $97,726 $111,168


LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $622 $1,223
Accrued liabilities 5,419 4,095
Deferred revenue 151 360
Current portion of capital lease obligations 1,514 2,011
Total current liabilities 7,706 7,689

Capital lease obligations, less current portion 2,186 1,565
Other long-term liabilities 3,000 500
Total long-term liabilities 5,186 2,065

Stockholders` equity:
Convertible preferred stock, $.001 par
value, 5,000,000 shares authorized; no
shares issued and outstanding at June 30,
2001 and December 31, 2000 -- --

Common stock, $.001 par value, 50,000,000
shares authorized; 21,057,583 and
20,913,151 shares issued and outstanding
at June 30, 2001 and December 31, 2000,
respectively 21 21
Additional paid-in capital 194,198 193,459
Accumulated other comprehensive income 862 270
Deferred compensation (175) (325)
Notes receivable from officers (1,131) (1,099)
Accumulated deficit (108,941) (90,912)
Total stockholders` equity 84,834 101,414
Total liabilities and stockholders` equity $97,726 $111,168


NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)

Three months ended Six months ended
June 30, June 30,
2001 2000 2001 2000
Revenues:
Sales $302 $164 $531 $164
Sponsored research 2,055 1,704 4,401 3,566
Contract and grant revenue 358 484 723 934
Total revenues 2,715 2,352 5,655 4,664

Operating expenses:
Cost of sales 230 12 400 12
Research and development 4,414 4,515 9,199 8,758
Selling, general and
administrative 5,406 3,344 10,192 5,625
Litigation and settlement
of patent matter 5,511 -- 6,309 --
Total operating expenses 15,561 7,871 26,100 14,395
Loss from operations (12,846) (5,519) (20,445) (9,731)

Interest income, net 1,092 1,406 2,418 1,940
Gain (loss) on foreign
currency transactions 4 -- (2) --
Net loss $ (11,750) $ (4,113) $ (18,029) $ (7,791)

Net loss per share -
basic and diluted $(0.56) $(0.20) $(0.87) $(0.40)

Number of shares used in
computing net loss per
share - basic and diluted 20,847 20,208 20,802 19,513

[ambobobo]

Nanogen Reports 2001 Second Quarter Results


/FROM PR NEWSWIRE LOS ANGELES 213-626-5500/ [STK] NGEN [IN] MTC BIO [SU] ERN CCA TO BUSINESS EDITOR:


















Nanogen Reports 2001 Second Quarter Results





SAN DIEGO, July 31 /PRNewswire/ -- Nanogen, Inc. (NASDAQ:NGEN) today announced its financial results for the second quarter ended June 30, 2001.




Total revenues for the quarter ended 2001 were $2.7 million compared to $2.4 million for the same period in 2000. Revenue recognized during the quarter was primarily earned in connection with sponsored research programs from the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $302,000 in revenue recognized during the quarter resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.





Nanogen sold three NanoChip(TM) Molecular Biology Workstations during the quarter ended June 30, 2001. The three sales included two sales recorded as product revenue and one sale recorded as sponsored research revenue and funded via a corporate alliance.





For the first six months of 2001, total revenues were $5.7 million as compared to $4.7 million for the same period in 2000. Revenue recognized during the six months ended June 30, 2001 was primarily earned in connection with sponsored research programs with the Company`s corporate alliances and from contracts or grants with government agencies. In addition, $531,000 in revenue recognized in the six months ended June 30, 2001 resulted from sales of NanoChip(TM) Molecular Biology Workstations and sales of NanoChip(TM) cartridges.





The Company`s cash, cash equivalents and short-term investment balance at June 30, 2001 was $78.4 million. During the quarter ended June 30, 2001, the Company incurred a one-time charge of $5 million related to a settlement of a patent litigation matter involving Motorola, Inc., Genometrix, Inc. and the Massachusetts Institute of Technology. Absent the impact of charges related to the litigation and settlement of this matter, total operating expenses for the second quarter of 2001 were $10.1 million, as compared to $7.9 million for the same period in 2000. For the first six months of 2001, absent these charges, total operating expenses were $19.8 million compared to $14.4 million for the same period in 2000. The increase in operating expenses for the second quarter of 2001 and for the first six months of 2001, as compared to the same periods in 2000, are primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization.





The reported net loss for the quarter and six-month period ended June 30, 2001, inclusive of the litigation and settlement charges noted above, was $11.8 million, or $0.56 per share and $18.0 million, or $0.87 per share, respectively. For the quarter ended June 30, 2001, excluding the litigation and settlement charges noted above of $5.5 million, the Company reported a net loss of $6.2 million or $0.30 per share, compared to a net loss of $4.1 million or $0.20 per share for the same period in 2000. For the first six months of 2001, excluding the litigation and settlement charges noted above of $6.3 million, the Company reported a net loss of $11.7 million or $0.56 per share, compared to a net loss of $7.8 million or $0.40 per share for the same period in 2000.





Highlights for the second quarter, ended June 30, 2001 include:





-- The formation of a joint venture with Aventis R&T named Nanogen








Recognomics GmbH, including the assignment by Aventis R&T of 18 patents








to this new joint venture. Funding for the joint venture is initially








provided by Aventis R&T.





-- Appointment of two executives: V. Randy White as Chief Executive








Officer and Gerard A. Wills as Chief Financial Officer.





-- Award of an additional six United States and three foreign patents to








Nanogen bringing the total number of U.S. patents to 27. In addition,








the joint venture between Nanogen and Becton Dickinson was issued its








first patent.





-- Initiation of external testing for High Throughput Screening of Protein








Kinases as an alternative application around Nanogen`s core electronics








technology.





Additionally, Nanogen resolved its litigation with Motorola, Genometrix and MIT by securing a license from Motorola to Claims 16 and 39 of U.S. Patent No. 5,653,939 entitled "Optical and Electrical Methods and Apparatus for Molecular Detection." This provides Nanogen the freedom to operate under patent claims relating to electronic hybridization. Nanogen resolved the litigation without having to provide Motorola access to Nanogen`s own technology. Nanogen remains the only current provider of commercially available electronic hybridization products.





"We are pleased with the progress we made during the second quarter, including progress toward our planned entry into the clinical diagnostics market," said Randy White, Ph.D., Nanogen`s Chief Executive Officer. "This included internal development of genetic content to be used with the NanoChip(TM) cartridges to support the clinical research market and eventually the clinical diagnostics market, where there is high demand for pre-made arrays. Additionally, we continued to build and train our sales and marketing team and applications specialists to support our customer base and commercialization efforts of the NanoChip(TM) Molecular Biology Workstation."





Webcast of Conference Call





Nanogen management will hold a conference call to discuss second quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available at http://www.videonewswire.com/event.asp?id=316 and through a link that is posted on Nanogen`s website at http://www.nanogen.com. A telephone replay of the conference call also will be available for 48 hours at 800-633-8284 (domestic) or 858-812-6440 (international), reservation #19399095. The webcast will be available on Nanogen`s website through August 7, 2001.





Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists, genomics laboratories and clinical research laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.





This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be successfully commercialized, whether the patented inventions can be successfully incorporated into commercial products, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding sales or placements of its NanoChip(TM) Molecular Biology Workstation as it deems appropriate and as required by law.

































NANOGEN, INC.


























CONSOLIDATED BALANCE SHEETS























(in thousands, except share data)





















































June 30, December 31,























































2001 2000




















































(unaudited)






























ASSETS





Current assets:







Cash and cash equivalents $20,419 $55,330







Short-term investments 57,938 39,759







Accounts receivable 1,413 1,322







Inventory 4,234 2,289







Other current assets 3,332 1,689





Total current assets 87,336 100,389





Property and equipment, net 5,444 5,373





Acquired technology rights, net 4,579 5,179





Restricted cash 164 164





Other assets 203 63





Total assets $97,726 $111,168















LIABILITIES AND STOCKHOLDERS` EQUITY





Current liabilities:







Accounts payable $622 $1,223







Accrued liabilities 5,419 4,095







Deferred revenue 151 360







Current portion of capital lease obligations 1,514 2,011





Total current liabilities 7,706 7,689





Capital lease obligations, less current portion 2,186 1,565





Other long-term liabilities 3,000 500





Total long-term liabilities 5,186 2,065





Stockholders` equity:







Convertible preferred stock, $.001 par








value, 5,000,000 shares authorized; no








shares issued and outstanding at June 30,








2001 and December 31, 2000 -- --







Common stock, $.001 par value, 50,000,000








shares authorized; 21,057,583 and








20,913,151 shares issued and outstanding








at June 30, 2001 and December 31, 2000,








respectively 21 21







Additional paid-in capital 194,198 193,459







Accumulated other comprehensive income 862 270







Deferred compensation (175) (325)







Notes receivable from officers (1,131) (1,099)





Accumulated deficit (108,941) (90,912)





Total stockholders` equity 84,834 101,414





Total liabilities and stockholders` equity $97,726 $111,168

































NANOGEN, INC.





















CONSOLIDATED STATEMENTS OF OPERATIONS


































(unaudited)





















(in thousands, except per share data)




































Three months ended Six months ended










































June 30, June 30,






































2001 2000 2001 2000





Revenues:







Sales $302 $164 $531 $164







Sponsored research 2,055 1,704 4,401 3,566







Contract and grant revenue 358 484 723 934





Total revenues 2,715 2,352 5,655 4,664





Operating expenses:







Cost of sales 230 12 400 12







Research and development 4,414 4,515 9,199 8,758







Selling, general and








administrative 5,406 3,344 10,192 5,625







Litigation and settlement








of patent matter 5,511 -- 6,309 --





Total operating expenses 15,561 7,871 26,100 14,395





Loss from operations (12,846) (5,519) (20,445) (9,731)





Interest income, net 1,092 1,406 2,418 1,940





Gain (loss) on foreign






currency transactions 4 -- (2) --





Net loss $ (11,750) $ (4,113) $ (18,029) $ (7,791)





Net loss per share -






basic and diluted $(0.56) $(0.20) $(0.87) $(0.40)





Number of shares used in






computing net loss per






share - basic and diluted 20,847 20,208 20,802 19,513

[tst89]

@all

Was haltet Ihr davon????? Irgendwie bin ich recht zwiegespalten, wobei die Erhöhung des Gesamtumsatzes sicherlich positiv zu werten ist.

Andererseits ist der Verlust auch auf die Erhöhung der Vermarktungskosten zurückzuführen......

Gebt mir Eure Meinungen!!

thanx
tst

[ambobobo]

@ tst89

Tja mein Englich grins..... ich muss
mich hier auf mein Translater verlassen.
Der Anstieg beim Umsatz ist sehr gut!
Die Kosten die anfallen sind nun mal da
und die Forschungskosten müssen ja steigen
das hoffe ich doch.
Insgesamt ist es ok niht toll aber ok
wir sollten ja auch bedenken in welcher
Wirtschaftslage wir sind.
Wer konnte den den Umsatz schon steigern?
Trotzdem würde ich mich über Meinungen und
eine Übersetztung freuen.

ambobobo